There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
Aquavit will officially unveil the Dermatox and Microtox programs at the Annual American Academy of Dermatology, the world's largest dermatology conference scheduled from March 25-29, 2022, in Boston, MA
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
Data to establish the safety profile and human dose of vaccine candidate
Moving well beyond the traditional approach of testing a vaccine’s collective response in large populations, this precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
Subscribe To Our Newsletter & Stay Updated
